Telecare, mobile apps, connected self-management tools. These are all types of digital health technologies that can be used to improve the lives of patients with long-term conditions and NHS Salford Clinical Commissioning Group (NHS Salford CCG) has a fund of £450,000 to evaluate them in the local community.
The Digital Health Innovation Call will look to fund the testing and development of innovative digital products, services and clinical practices that aim to improve the experience and outcomes of patients in the Salford community. Applications are sought which align to the following NHS Salford CCG strategy group innovation priorities:
- Early Detection
- Self-care/Self-management including supporting patients/patient groups
Children & Young People
- Mental Wellbeing
- SEND (Special Educational Needs & Disability)
- Early Intervention and Prevention across issues for children and young people
- Improving medicines safety
- Improving patients getting better outcomes from their medicines
- Reducing medicines waste
- Improving medicines reconciliation at transfers of care
Mental Health –
- Improving & maintaining the physical health of people with serious mental illness
- Care Navigators for patients newly diagnosed with a mental health condition
- Digital solutions in mental health
Systems Resilience –
- Technological solutions to help patients self-manage/manage at home/avoid hospital attendance or admission
- Support to ensure patients appropriately access the right urgent care services for the right care
- Pathways or interventions that prevent A&E attendance or prevent ambulance conveyance or avoid admissions
Community Based Care –
- Increase collaborative working across all community-based partners
- Safer discharge into the community
Engagement & Experience –
- Responding to Needs Assessments undertaken through the city’s Joint Strategic Needs Assessment Programme
- Using technology to obtain patient feedback on existing services and new plans
- Motivating behavior change in our local population to live healthier lifestyles, self-care more and support others in local communities
The call is open to companies, NHS organisations, voluntary organisations, universities and independent innovators, who are invited to apply for awards of up to £125,000 by submitting their outline proposal online using the link below:
Delivered in partnership with TRUSTECH, the North West NHS Innovation Service, the Digital Health Innovation Call looks to identify solutions that demonstrate a potential return on investment as well as an impact on the Salford Locality Plan.
Successful projects, which will need to be delivered within a 12-month timescale starting in 2017, will help NHS Salford CCG to:
- Enable Primary and Community Care to become part of the safest health economy;
- Improve the interference between primary and secondary care; or
- Align to strategy group innovation priorities.
Selected applicants will be invited to compete for the opportunity to work with NHS Salford CCG to implement their project. This will involve attending a marketplace where they will be required to demonstrate their innovations to NHS Salford CCG staff and patients, as well as the concluding step in the application process, which will see the final few applicants pitch to a panel of experts in a Dragons’ Den in October.
Subject to due diligence, those that are successful will be notified in November 2016 and will be matched with a suitable community healthcare service to begin mapping out the evaluation.
The Digital Health Innovation Call is open for applications now. Applications must be submitted by no later than 5pm on 23rd August 2016.
From l to r: Dr Steve Pleasance, Head of Industry at the Royal Society of Chemistry, Prof Steve Yeates, Sci-Tron Director and School of Chemistry, Dr Scott Lewis, Sci-Tron Director and School of Chemistry, Hugh Dennis
University of Manchester spin-out, Sci-Tron Ltd, fought off stiff competition to win first prize in the Materials category at the Royal Society of Chemistry’s annual Emerging Technologies Competition 2016.
40 shortlisted entrants, which included another University spin-out Opticin Ltd, pitched their ideas to a panel of expert judges at Chemistry Means Business in London on June 15th, a two-day event for the chemistry-using industry by the Royal Society of Chemistry. The winners were announced at an award ceremony hosted by TV personality Hugh Dennis as part of the same event.
Sci-Tron, co-founded by Dr Scott Lewis, Professor Richard Winpenny and Professor Stephen Yeates from the School of Chemistry, is a nanotechnology specialist working with novel nano materials. These include advanced electron beam resists for the production of integrated circuits and state-of-the-art resins for 3D bio-imaging. Sci-Tron’s electron beam lithography resist materials will enable the fabrication of masks for the next generations of semiconductor manufacturing processes, unlocking the development of more complex, higher performance integrated circuits (ICs) with lower power consumption. Benefits of advanced ICs include the possibility to add more computing power and ‘intelligence’ at lower cost.
Sci-Tron co-founder Dr Scott Lewis comments: “This competition is highly competitive and prestigious so we are delighted to have been awarded first prize. To have industry recognise the potential of this new technology is extremely positive and we hope that our technology will go on to a significant impact within the semiconductor industry.”
Applications were judged on the degree of innovation of the technology, its potential impact, and the quality of the science behind it. Sci-Tron will receive tailored business support from one of the Royal Society of Chemistry’s multinational partner companies, business training, media support, and a cash prize of £20,000.
Dr Steve Pleasance, Head of Industry at the Royal Society of Chemistry said: “Increasing innovation in the chemical sciences is one of the key elements of the Royal Society of Chemistry’s industry strategy.
“Our Emerging Technologies competition, now in its fourth year and supported by our industry partners, is proving to be highly successful in accelerating the commercialisation of the cutting-edge research taking place in both universities and small companies.”
Winning the competition gives businesses the platform they need to make the industry aware of their technology. Since the initiative began in 2013, winners have gone on to raise a combined total of over £16 million in further funding, grown their companies and entered commercial contracts.
A previous winner went on to secure US$1.7 million of funding from the Bill and Melinda Gates Foundation to develop their novel treatment for iron deficiency anaemia, whilst another received support from GSK and was awarded over £2.5 million to take their enzyme catalysis technology towards market.
You can find out more about Sci-Tron at www.sci-tron.com
Another Manchester success was Eksagon Group, a start up company based at the University, who picked up second prize in the energy & environment category. Eksagon utilises the unique physicochemical properties of 2D materials to boost the performance of energy systems. You can read the full story here.
This week The University of Manchester has launched a new company to develop and commercialise products based on its Graphene technology.
Graphene Enabled Systems Limited, headquartered in the University’s Innovation Centre (UMIC) on Grafton Street in Manchester, is wholly owned by the University and is led by its newly appointed CEO, Andrew Wilkinson.
CEO, Andrew Wilkinson
The company’s mission is to create a number of highly profitable spin-out businesses based on the University’s Graphene patent portfolio. It is expected that many of these future spin-out businesses will be based in and around Manchester, creating new jobs in the region and benefiting the local economy.
Using the University’s patents and working closely with its Graphene research scientists, Graphene Enabled is seeking new markets for graphene-based products. Once these markets have been identified, Graphene Enabled will create high-quality product prototypes which will showcase the technology to potential industrial partners and customers.
Graphene Enabled will deliver the first product demonstrators within twelve months of the company’s formation. As an important part of the University’s Graphene strategy, Graphene Enabled is working in close collaboration with the University’s research teams, innovation and IP groups (UMI3 and UMIP), the National Graphene Institute (NGI) and, in 2017 and beyond, the new Graphene Engineering Innovation Centre (GEIC) and the Sir Henry Royce Institute for Advanced Materials.
Commenting on the company’s launch, Andrew Wilkinson said:
“The University of Manchester has been at the forefront of this scientific breakthrough and, based on this, we are now in a unique position to harness the full potential of Graphene and other 2D materials. At Graphene Enabled, we plan to create a huge range of exciting new products such as stronger, lighter composite materials; new flexible conductive inks; super-tough abrasion resistant coatings; special filters designed only to let selected materials pass through them and a huge array of new high-performance electronic components and energy strorage devices such as batteries and capacitors. All of these potential new products are made possible by the work that is being carried out at the University and our job, at Graphene Enabled is to work with industrial partners, investors and entrepreneurs to turn this innovative science into real products. “
Graphene Enabled branding
Graphene Enabled branding
University of Manchester academics Sir Kostya Novoselov and Sir Andre Geim were awarded the Nobel prize in 2010 for their ground-breaking experiments which opened up this new field of science.
The development of Graphene Enabled has been supported by the University’s agent for IP commercialisation, UMIP.
Although Graphene Enabled is internationally focused, the creation of any new spin-outs will potentially result in a cluster of 2D technology businesses in the Northwest, bringing benefits to Manchester and the wider UK economy.
All products which are developed through the commercialisation programme will feature the Graphene Enabled logo which reflects that this is a cutting-edge University of Manchester technology.
For further information about Graphene Enabled, please visit our website www.graphene-enabled.com and follow us on Twitter @GrapheneEnabled.
New stem cell company, StrataStem, which is able to study ‘Alzheimer’s disease in a dish’, has just launched in Manchester. Spun-out of The University of Manchester by UMIP, StrataStem was founded by Stem Cell Research Fellow, Dr Lisa Mohamet and Dr Chris Ward, a Reader in Stem Cell Biology.
With its patented technology, StrataStem accelerates the process of making neural cells from patients’ stem cells, while eliminating the need for the use of animal models for testing.
A significant advantage of this method is that it is based on human cells and will be a better way to assess new drugs for the treatment of individuals with Alzheimer’s disease.
The founders have just launched a new website www.stratastem.com and are hoping to raise funds so products can be launched to market.
Dr Mohamet said: “We are a stem cell based technology company that uses induced stem cells as a model to help us understand more about Alzheimer’s disease.
“We have chosen to focus our efforts on Alzheimer’s disease because there’s a huge unmet clinical need.
“There have been no new drugs in the past 10 years to effectively treat the symptoms of Alzheimer’s disease, let alone a cure. We hope to repurpose drugs that already work for other conditions that could provide us with a shortcut to new treatments.”
StrataStem’s customers will be researchers, pharmaceutical and bio-tech companies.
They can utilise StrataStem’s technology to increase the chances of both understanding more about the disease and creating a drug both faster and cheaper, so that benefit can be passed to Alzheimer’s sufferers.
Dr Mohamet said: “This exciting technology allows us to transform any cell – such as hair or skin – from a patient with a disease into a neuron, creating a replica model of the patients’ cells in a dish, previously, this was only possible post-mortem.
“StrataStem’s patented technology has made the whole process quicker and more robust. “
Dr Mohamet said having this ‘better model to test drugs’ means failure is less likely.
She also said “The company is now entering an exciting growth phase and is seeking strategic investment to expedite its commercial activities.
“We’ve received funding from The University of Manchester, The UMIP Premier Fund (with support from UMIP and MTI Partners) and the Biotechnology and Biological Sciences Research Council (BBSRC).
“It’s an exciting time as we are bringing together stem cell technology and drug discovery, which can revolutionise medicine and how we treat patients.
“To be part of that is amazing in itself and if we get the right partner on board this will make a genuine difference to people’s lives.”
Follow StrataStem on Twitter @StrataStem
Dr Lisa Mohamet
Neurons grown from induced stem cells from an individual with Alzheimer’s Disease